RS63687B1 - Injektabilne kompozicije triterpenoidnih antifungalnih jedinjenja inkapsuliranih u lipozome - Google Patents
Injektabilne kompozicije triterpenoidnih antifungalnih jedinjenja inkapsuliranih u lipozomeInfo
- Publication number
- RS63687B1 RS63687B1 RS20220981A RSP20220981A RS63687B1 RS 63687 B1 RS63687 B1 RS 63687B1 RS 20220981 A RS20220981 A RS 20220981A RS P20220981 A RSP20220981 A RS P20220981A RS 63687 B1 RS63687 B1 RS 63687B1
- Authority
- RS
- Serbia
- Prior art keywords
- formula
- compound
- pharmaceutically acceptable
- hydrate
- acceptable salt
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4196—1,2,4-Triazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/7056—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
- A61K9/1277—Preparation processes; Proliposomes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Dispersion Chemistry (AREA)
- Dermatology (AREA)
- Molecular Biology (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oncology (AREA)
- Biochemistry (AREA)
- Communicable Diseases (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Steroid Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862612893P | 2018-01-02 | 2018-01-02 | |
| PCT/US2018/067216 WO2019135954A1 (en) | 2018-01-02 | 2018-12-21 | Injectable compositions of triterpenoid antifungals encapsulated in liposomes |
| EP18834263.8A EP3735226B1 (en) | 2018-01-02 | 2018-12-21 | Injectable compositions of triterpenoid antifungals encapsulated in liposomes |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RS63687B1 true RS63687B1 (sr) | 2022-11-30 |
Family
ID=65024141
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RS20220981A RS63687B1 (sr) | 2018-01-02 | 2018-12-21 | Injektabilne kompozicije triterpenoidnih antifungalnih jedinjenja inkapsuliranih u lipozome |
Country Status (27)
| Country | Link |
|---|---|
| US (3) | US20200338002A1 (https=) |
| EP (2) | EP4137123A1 (https=) |
| JP (3) | JP7378401B2 (https=) |
| KR (1) | KR102694692B1 (https=) |
| CN (2) | CN115998684A (https=) |
| AU (1) | AU2018399599B2 (https=) |
| CA (1) | CA3087176A1 (https=) |
| DK (1) | DK3735226T3 (https=) |
| EA (1) | EA202091626A1 (https=) |
| ES (1) | ES2927051T3 (https=) |
| HR (1) | HRP20221295T1 (https=) |
| HU (1) | HUE060400T2 (https=) |
| IL (2) | IL275758B2 (https=) |
| LT (1) | LT3735226T (https=) |
| MA (1) | MA51514A (https=) |
| MD (1) | MD3735226T2 (https=) |
| MX (1) | MX2020006992A (https=) |
| PL (1) | PL3735226T3 (https=) |
| PT (1) | PT3735226T (https=) |
| RS (1) | RS63687B1 (https=) |
| SA (1) | SA520412362B1 (https=) |
| SG (1) | SG11202006313WA (https=) |
| SI (1) | SI3735226T1 (https=) |
| SM (1) | SMT202200427T1 (https=) |
| TW (2) | TWI857944B (https=) |
| UA (1) | UA126096C2 (https=) |
| WO (1) | WO2019135954A1 (https=) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3087176A1 (en) * | 2018-01-02 | 2019-07-11 | Scynexis, Inc. | Injectable compositions of triterpenoid antifungals encapsulated in liposomes |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5756472A (en) | 1996-01-31 | 1998-05-26 | Merck & Co., Inc. | Antifungal agent obtained from hormonema |
| US7718189B2 (en) * | 2002-10-29 | 2010-05-18 | Transave, Inc. | Sustained release of antiinfectives |
| NZ548195A (en) * | 2004-01-14 | 2011-01-28 | Gilead Sciences Inc | Lipid-based dispersions useful for drug delivery |
| JP5245057B2 (ja) | 2006-04-03 | 2013-07-24 | メルク・シャープ・アンド・ドーム・コーポレーション | 抗真菌剤 |
| CN101861150B (zh) * | 2007-09-28 | 2014-07-16 | 默克夏普和道赫莫公司 | 抗真菌制剂 |
| JP2011518844A (ja) * | 2008-04-25 | 2011-06-30 | ナノバイオ コーポレーション | 真菌、酵母および糸状菌感染症を治療するためのナノエマルション |
| AU2009275230A1 (en) * | 2008-07-23 | 2010-01-28 | Targeted Delivery Technologies Limited | Methods of administering topical antifungal formulations for the treatment of fungal infections |
| WO2010019204A1 (en) * | 2008-08-12 | 2010-02-18 | Merck Sharp & Dohme Corp. | Antifungal agents |
| ES2593027T3 (es) * | 2009-03-30 | 2016-12-05 | Eisai R&D Management Co., Ltd. | Composición liposomal |
| HRP20220544T1 (hr) * | 2015-01-19 | 2022-08-05 | Scynexis, Inc. | Nove soli i polimorfi scy-078 |
| CA3087176A1 (en) * | 2018-01-02 | 2019-07-11 | Scynexis, Inc. | Injectable compositions of triterpenoid antifungals encapsulated in liposomes |
-
2018
- 2018-12-21 CA CA3087176A patent/CA3087176A1/en active Pending
- 2018-12-21 MD MDE20201148T patent/MD3735226T2/ro unknown
- 2018-12-21 AU AU2018399599A patent/AU2018399599B2/en active Active
- 2018-12-21 RS RS20220981A patent/RS63687B1/sr unknown
- 2018-12-21 HU HUE18834263A patent/HUE060400T2/hu unknown
- 2018-12-21 LT LTEPPCT/US2018/067216T patent/LT3735226T/lt unknown
- 2018-12-21 CN CN202310046755.4A patent/CN115998684A/zh active Pending
- 2018-12-21 DK DK18834263.8T patent/DK3735226T3/da active
- 2018-12-21 MX MX2020006992A patent/MX2020006992A/es unknown
- 2018-12-21 UA UAA202004935A patent/UA126096C2/uk unknown
- 2018-12-21 WO PCT/US2018/067216 patent/WO2019135954A1/en not_active Ceased
- 2018-12-21 EP EP22187779.8A patent/EP4137123A1/en active Pending
- 2018-12-21 IL IL275758A patent/IL275758B2/en unknown
- 2018-12-21 SG SG11202006313WA patent/SG11202006313WA/en unknown
- 2018-12-21 EP EP18834263.8A patent/EP3735226B1/en active Active
- 2018-12-21 HR HRP20221295TT patent/HRP20221295T1/hr unknown
- 2018-12-21 ES ES18834263T patent/ES2927051T3/es active Active
- 2018-12-21 SI SI201830746T patent/SI3735226T1/sl unknown
- 2018-12-21 IL IL318793A patent/IL318793A/en unknown
- 2018-12-21 PL PL18834263.8T patent/PL3735226T3/pl unknown
- 2018-12-21 MA MA051514A patent/MA51514A/fr unknown
- 2018-12-21 US US16/958,691 patent/US20200338002A1/en not_active Abandoned
- 2018-12-21 JP JP2020536766A patent/JP7378401B2/ja active Active
- 2018-12-21 EA EA202091626A patent/EA202091626A1/ru unknown
- 2018-12-21 SM SM20220427T patent/SMT202200427T1/it unknown
- 2018-12-21 CN CN201880087851.0A patent/CN111655237B/zh active Active
- 2018-12-21 PT PT188342638T patent/PT3735226T/pt unknown
- 2018-12-21 KR KR1020207022062A patent/KR102694692B1/ko active Active
- 2018-12-27 TW TW107147395A patent/TWI857944B/zh active
- 2018-12-27 TW TW112144149A patent/TWI862280B/zh active
-
2020
- 2020-06-30 SA SA520412362A patent/SA520412362B1/ar unknown
-
2022
- 2022-10-04 US US17/960,076 patent/US20230277455A1/en not_active Abandoned
-
2023
- 2023-10-31 JP JP2023187032A patent/JP2024012452A/ja not_active Withdrawn
-
2024
- 2024-03-18 US US18/608,350 patent/US20250082574A1/en active Pending
-
2025
- 2025-04-01 JP JP2025060460A patent/JP2025106349A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20230364067A1 (en) | Antifungal agents with enhanced activity in acidic ph | |
| JP2025106349A (ja) | リポソームの中にカプセル化されたトリテルペノイド抗真菌薬の注射可能な組成物 | |
| HK40090116A (en) | Injectable compositions of triterpenoid antifungals encapsulated in liposomes | |
| HK40040387A (en) | Injectable compositions of triterpenoid antifungals encapsulated in liposomes | |
| HK40040387B (en) | Injectable compositions of triterpenoid antifungals encapsulated in liposomes | |
| HK40036677B (en) | Injectable compositions of triterpenoid antifungals encapsulated in liposomes | |
| EA045936B1 (ru) | Инъецируемые композиции, обладающие противогрибковой активностью, и способы их получения и применения | |
| BR112020013448B1 (pt) | Composição injetável, método para preparar uma composição injetável, e, uso da composição injetável | |
| HK40036677A (en) | Injectable compositions of triterpenoid antifungals encapsulated in liposomes | |
| Grillot et al. | Systemic antifungal agents |